Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.

Movement disorders : official journal of the Movement Disorder Society - 1 May 2006

Strong Judith A, Dalvi Arif, Revilla Fredy J, Sahay Alok, Samaha Frederick J, Welge Jeffrey A, Gong Jianhua, Gartner Maureen, Yue Xia, Yu Lei

Abstract excerpt

Parkinson's disease (PD) patients vary widely in their response to levodopa treatment, and this variation may be partially genetic in origin. We determined whether particular dopamine and opioid receptor polymorphisms were associated with risk of earlier onset of dyskinesia side effects during levodopa therapy. Smoking status was also examined. The 92 subjects were recruited from the movement disorders clinic of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Dyskinesia, Drug-Induced

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Levodopa

Share to Parkinson Disease

Share to Receptors, Dopamine

Share to Receptors, Opioid, mu

Share to Smoking

Source

Identifiers

PMID: 16435402
DOI: 10.1002/mds.20785

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.PMID 16435402Read ↗

Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.Semantic proximity Read ↗

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD.Semantic proximity Read ↗

The role of genetic factors in the occurrence of levodopa-induced motor complications in Parkinson's disease.Semantic proximity Read ↗

The Role of Single Nucleotide Polymorphisms of Monoamine Oxidase B, Dopamine D2 Receptor, and DOPA Decarboxylase Receptors Among Patients Treated for Parkinson's Disease.Semantic proximity Read ↗

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.Semantic proximity Read ↗

Smoking, genes encoding dopamine pathway and risk for Parkinson's disease.Semantic proximity Read ↗

Pharmacogenetics and levodopa induced motor complicationsSemantic proximity Read ↗

MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.Semantic proximity Read ↗

Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.Semantic proximity Read ↗

Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's diseaseSemantic proximity Read ↗

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.Semantic proximity Read ↗

Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.